Sigrid Therapeutics Announces SiPore15 Data Presentation at the American Diabetes Association 79th Scientific Sessions

By April 10, 2019 No Comments

Stockholm, Sweden, 9 April 2019 – Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies targeting metabolic diseases and disorders, today announces that clinical data for the Company’s lead product candidate, SiPore15TM, has been selected for presentation as late breaking news at the American Diabetes Association (ADA) 79th Scientific Session, June 7-11, 2019 in San Francisco, California.

Leave a Reply